The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
BG-75202 features among several projects starting first-in-human trials.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
